Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $293M | $390M | $588M |
| Revenue growth | — | 33.4% | 50.6% |
| Gross profit | $194M | $300M | $468M |
| Gross margin | 66.3% | 76.8% | 79.6% |
| Operating income | -$131M | -$31.9M | -$546M |
| Operating margin | -44.6% | -8.2% | -92.9% |
| Net income | -$108M | -$11.9M | -$528M |
| Net margin | -36.9% | -3.1% | -89.9% |
| EPS (diluted) | -$8.31 | -$0.88 | -$7.77 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$63.9M | $49.0M | $171M |
| Capital expenditures | $1.98M | $1.04M | $708K |
| Free cash flow | -$65.9M | $48.0M | $171M |
| Share buybacks | $0.00 | $0.00 | $65.0M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $235M | $301M | $208M |
| Total assets | — | $673M | $745M |
| Total liabilities | — | $257M | $366M |
| Shareholders' equity | -$424M | -$435M | $179M |
| Retained earnings | — | -$523M | -$1.05B |
| Shares (wtd avg diluted) | 13.0M | 13.6M | 54.6M |
Every figure is extracted from Hinge Health, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.